Piroxicam Premedication for Postendodontic Pain in Non-vital Mandibular Molars

NCT03998826 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2019-07-16

No results posted yet for this study

Summary

The aim of the study is to evaluate the effect of piroxicam (20mg) compared to placebo on post-endodontic pain of single-visit endodontic treatment of non-vital mandibular molars.

Conditions

  • Non-Vital Tooth

Interventions

DRUG

Piroxicam

20mg piroxicam

DRUG

Placebo

placebo

Sponsors & Collaborators

  • Cairo University

    lead OTHER

Principal Investigators

  • Asmaa FE Mohamed, B.D.S · Cairo University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-01
Primary Completion
2020-09-01
Completion
2020-12-01

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03998826 on ClinicalTrials.gov